FindTrial
Sign In

Dysregulated Tyrosine Kinase Signaling in Leukemia

Dysregulated Tyrosine Kinase Signaling in Leukemia

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00277056
Enrollment
30
Registered
2006-01-13
Start date
2002-05-31
Completion date
2005-10-31
Last updated
2024-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia

Keywords

leukemia

Brief summary

Dysregulated Tyrosine Kinase Signaling in Leukemia

Detailed description

Purpose: to look at a number of proteins in the abnormal cells in the blood and/or bone marrow. These proteins make a cell grow or prevent the cell from dying

Interventions

None listed

Sponsors

University of New Mexico
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients must have newly diagnosed or relapsed leukemia. * Patients must sign an informed consent. * Patients will not be excluded if they are receiving chemotherapy. * Patients with CML, AML, ALL, T/NK leukemia, myelodysplasia, or myeloproliferative disorders will be eligible. * Patients must be =\> 18 years of age.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026